DENCARE (CHONGQING) ORAL CARE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.76 CNY | +0.25% |
|
-0.83% | -16.07% |
| 05-28 | Dencare Oral Care Co., Ltd. Approves Cash Dividend for the Year 2023 | CI |
| 04-26 | Dencare Oral Care Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- With a 2024 P/E ratio at 25.55 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Sector: Household Products
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -16.07% | 562M | - | ||
| 0.00% | 99.19M | - | - | |
| +211.55% | 74.05M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 001328 Stock
- Ratings Dencare (Chongqing) Oral Care Co., Ltd.